Revised Geneva Score Calculator

Calculate revised geneva score quickly with our cardiovascular system tool. Get results based on evidence-based formulas with clear explanations.

Share this calculator

X Facebook LinkedIn

Formula

Revised Geneva Score = Sum of weighted clinical variables (0-25 points)

Variables include age > 65 (+1), previous PE/DVT (+3), recent surgery/fracture (+2), active malignancy (+2), unilateral leg pain (+3), hemoptysis (+2), heart rate 75-94 (+3) or >= 95 (+5), and leg pain on palpation/unilateral edema (+4/+1). Scores 0-3 = low, 4-10 = intermediate, 11+ = high probability.

Worked Examples

Example 1: Low Probability PE Assessment

Problem: A 55-year-old patient presents with chest pain. No prior VTE history, no recent surgery, no cancer. Heart rate 70 bpm. No leg symptoms or hemoptysis.

Solution: Scoring: Age > 65: No (0 points), Previous PE/DVT: No (0), Recent surgery: No (0), Active cancer: No (0), Unilateral leg pain: No (0), Hemoptysis: No (0), Heart rate 70 < 75: (0 points), Leg palpation pain/edema: No (0).\nTotal Revised Geneva Score = 0\nProbability category: Low (0-3 points)\nPE prevalence in this group: approximately 8%

Result: Score: 0/25 | Low Probability | Recommend D-dimer testing; if negative, PE excluded

Example 2: High Probability PE Assessment

Problem: A 72-year-old patient with prior DVT, active lung cancer, heart rate 100 bpm, unilateral leg swelling with pain on palpation, and recent hemoptysis.

Solution: Scoring: Age > 65: Yes (+1), Previous PE/DVT: Yes (+3), Recent surgery: No (0), Active cancer: Yes (+2), Unilateral leg pain: Yes (+3), Hemoptysis: Yes (+2), Heart rate >= 95: (+5), Leg palpation pain + edema: Yes (+4 + 1 = +5).\nTotal Revised Geneva Score = 1+3+2+3+2+5+5 = 21\nProbability category: High (> 10 points)\nPE prevalence in this group: approximately 74%

Result: Score: 21/25 | High Probability | Proceed directly to CTPA; consider empiric anticoagulation

Frequently Asked Questions

What is the Revised Geneva Score and what does it assess?

The Revised Geneva Score is a validated clinical prediction rule used to estimate the pretest probability of pulmonary embolism (PE) in patients presenting with suspected PE symptoms. Originally developed in 2006 by Le Gal and colleagues, it was designed to simplify the original Geneva Score while maintaining diagnostic accuracy. The score uses eight clinical variables that are entirely objective, meaning they do not require subjective clinical assessment. This objectivity is a major advantage over the Wells Score, which includes a somewhat subjective criterion. The Revised Geneva Score stratifies patients into low, intermediate, and high probability categories, guiding subsequent diagnostic workup decisions including D-dimer testing and CT pulmonary angiography.

How does the Revised Geneva Score differ from the Wells Score for PE?

Both the Revised Geneva Score and the Wells Score are clinical prediction rules for pulmonary embolism, but they differ in important ways. The Wells Score includes a subjective criterion asking whether PE is the most likely diagnosis, which can introduce variability between clinicians. The Revised Geneva Score uses only objective, standardized variables, making it more reproducible across different healthcare providers and settings. The Wells Score uses a two-tier (PE likely/unlikely) or three-tier (low/moderate/high) system, while the Revised Geneva Score uses three probability levels. Studies comparing both scores show similar overall diagnostic accuracy, with c-statistics around 0.70 to 0.75 for each. Many clinicians prefer the Revised Geneva Score for research settings due to its objectivity, while the Wells Score remains popular in clinical practice.

What clinical variables are included in the Revised Geneva Score?

The Revised Geneva Score evaluates eight clinical variables. Age over 65 years adds 1 point. Previous history of pulmonary embolism or deep vein thrombosis adds 3 points. Surgery under general anesthesia or lower limb fracture within the past month adds 2 points. Active malignant condition (solid or hematologic, currently active or considered cured for less than one year) adds 2 points. Unilateral lower limb pain adds 3 points. Hemoptysis (coughing up blood) adds 2 points. Heart rate between 75 and 94 beats per minute adds 3 points, while a heart rate of 95 or above adds 5 points. Pain on lower limb deep venous palpation and unilateral edema adds 4 points. The maximum possible score is 25 points.

How should D-dimer testing be interpreted alongside the Geneva Score results?

D-dimer testing plays a crucial role in the diagnostic algorithm when combined with the Revised Geneva Score. For patients with a low probability score (0 to 3 points), a negative D-dimer test can safely exclude pulmonary embolism without further imaging, as the negative predictive value exceeds 99 percent in this group. For intermediate probability patients (4 to 10 points), D-dimer testing is recommended as the next step because imaging all these patients would be costly and expose many to unnecessary radiation. A positive D-dimer in this group warrants CT pulmonary angiography. For high probability patients (11 or more points), D-dimer testing is generally not recommended because the clinical suspicion is high enough to warrant direct imaging, and a negative D-dimer cannot reliably exclude PE in this group.

What are the limitations of the Revised Geneva Score in clinical practice?

The Revised Geneva Score has several important limitations that clinicians should understand. It was primarily validated in emergency department populations and may not perform as well in outpatient or critically ill inpatient settings. The score does not account for certain risk factors such as hormonal contraceptive use, recent long-distance travel, thrombophilia, or obesity, which can influence PE probability. In pregnant patients, the score has not been adequately validated and should be used with extreme caution. The score may also underestimate risk in younger patients with significant risk factors because age contributes only one point. Additionally, the heart rate criterion can be affected by medications such as beta-blockers or conditions causing tachycardia unrelated to PE, potentially leading to misclassification.

How does heart rate influence the Revised Geneva Score and why is it weighted heavily?

Heart rate is one of the most heavily weighted variables in the Revised Geneva Score, contributing up to 5 points for rates at or above 95 beats per minute. This heavy weighting reflects the strong physiological relationship between pulmonary embolism and tachycardia. When a blood clot obstructs pulmonary arteries, the right ventricle must work harder to pump blood through the remaining patent vessels, leading to increased heart rate as a compensatory mechanism. Additionally, PE triggers sympathetic nervous system activation due to hypoxemia and hemodynamic stress. Research shows that tachycardia is present in approximately 40 to 50 percent of patients with confirmed PE, making it one of the most common clinical signs. However, clinicians must recognize that tachycardia has many causes, and its presence alone is neither sensitive nor specific enough for PE diagnosis.